C(O)(C(F)(F)F)=O.[Br:8][C:9]1[C:17]2[C:16]([O:18][CH:19]3[CH2:24][CH2:23][CH2:22][N:21](NC(OC(C)(C)C)=O)[CH2:20]3)=[N:15][CH:14]=[N:13][C:12]=2[O:11][C:10]=1[C:33]1[CH:38]=[CH:37][CH:36]=[CH:35][CH:34]=1>ClCCl>[Br:8][C:9]1[C:17]2[C:16]([O:18][CH:19]3[CH2:24][CH2:23][CH2:22][NH:21][CH2:20]3)=[N:15][CH:14]=[N:13][C:12]=2[O:11][C:10]=1[C:33]1[CH:38]=[CH:37][CH:36]=[CH:35][CH:34]=1Add a total of 3.4 ml of TFA in several portions at RT to a solution of 1.05 g (2.21 mmol) of tert-butyl rac-3-[(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)oxy]-1-piperidinecarbamate in 2 ml of dichloromethane, and stir at RT for 2 h. Then dilute with dichloromethane, add satd. sodium hydrogencarbonate solution cautiously to the solution and then wash twice with satd. sodium hydrogencarbonate solution. Dry the organic phase over magnesium sulphate and concentrate under reduced pressure. Stir the oily residue with methanol, filter off the precipitated solid with suction and wash with methanol. Combine mother liquor and wash solution, concentrate under reduced pressure and stir again with a little methanol. Filter off the resulting crystals with suction, wash with methanol and combine with the first crystal fraction. A total of 550 mg (66.4% of theory) of the target compound are obtained.